Kiniksa Pharmaceuticals International, plc KNSA Total Current Liabilities
Total Current Liabilities at other companies
Other financials
Where this comes from
Reported directly by Kiniksa Pharmaceuticals International, plc in its filing.
Tagged under the XBRL concept us-gaap:LiabilitiesCurrent.
The official record: Kiniksa Pharmaceuticals International, plc’s 10-Q, filed April 28, 2026, on SEC EDGAR. View the filing →
Ask your AI about Kiniksa Pharmaceuticals International, plc's total current liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Kiniksa Pharmaceuticals International, plc's total current liabilities?
- Kiniksa Pharmaceuticals International, plc (KNSA) reported total current liabilities of $156.61M in Q1 2026.
- How has Kiniksa Pharmaceuticals International, plc's total current liabilities changed year-over-year?
- Kiniksa Pharmaceuticals International, plc's total current liabilities increased by 61.0% year-over-year, from $97.27M to $156.61M.
- What is the long-term trend for Kiniksa Pharmaceuticals International, plc's total current liabilities?
- Over 5 years (2020 to 2025), Kiniksa Pharmaceuticals International, plc's total current liabilities has grown at a 34.3% compound annual growth rate (CAGR), from $31.85M to $139.18M.
- What does total current liabilities mean?
- The sum of all obligations due within one year — payables, accrued expenses, current debt, deferred revenue, and other short-term liabilities.